LAUSR

Conclusions Adoptive T cell therapies have shown promising results in clinical trials for solid tumor indications, but efficacy and safety are still suboptimal. We constructed non-replicating and replicating adenoviruses encoding the immunostimulatory cytokines Tumor Necrosis Factor alpha (TNFa) and Interleukin-2 (IL-2), and studied their ability to enhance adoptive T cell therapy. TCR transgenic OT-I T cells were used in mouse studies, while tumor-infiltrating lymphocytes (TIL) grown from syngeneic Syrian hamster tumors were used in studies with oncolytic adenoviruses, since this rodent species supports human adenovirus replication in its tissues. In addition, delivery of IL2 into solid tumors from an adenoviral vector was compared directly with systemic IL-2 administration in the context of T cell transfer.